Literature DB >> 21271313

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules.

Seong-Jang Kim1, Bo Hyun Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim.   

Abstract

OBJECTIVE: To assess usefulness of dual-time-point (18)F FDG PET/CT to differentiate malignant from benign thyroid nodules and predict the potential factor for malignancy.
METHODS: Fifty patients (age 38-83 years, mean 58 ± 10.6 years) with thyroid nodule were recruited. The (18)F FDG PET/CT images were analyzed visually and quantitatively.
RESULTS: The optimal visual grade of early and delayed images was >grade 3. When SUV(max1) of >2.9 was used as cut off point, the sensitivity and specificity were 55.5 and 63.4%. When SUV(max2) was >3.1, the sensitivity and specificity were 88.8 and 43.9%. When %ΔSUV(max) was ≤9.09%, the sensitivity and specificity were 33.3 and 87.8%. ROC analyses showed that all indices had similar efficacy without significances. No definite predictor could be found for malignant nodules.
CONCLUSION: The dual-time-point (18)F FDG PET/CT is not a useful method for differentiating malignant and benign nodules.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271313     DOI: 10.1007/s12149-011-0468-0

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  9 in total

1.  The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma.

Authors:  Sinae Lee; Taegyu Park; Soyeon Park; Kisoo Pahk; Seunghong Rhee; Jaehyuk Cho; Eugene Jeong; Sungeun Kim; Jae Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2013-12-06

Review 2.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

3.  A prospective cohort study to assess the role of FDG-PET in differentiating benign and malignant follicular neoplasms.

Authors:  K Alok Pathak; Andrew L Goertzen; Richard W Nason; Thomas Klonisch; William D Leslie
Journal:  Ann Med Surg (Lond)       Date:  2016-10-31

4.  The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions.

Authors:  Ri Sa; Hong-Guang Zhao; Yu-Yin Dai; Feng Guan
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Focal Thyroid Incidentalomas on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis on Prevalence, Risk of Malignancy and Inconclusive Fine Needle Aspiration.

Authors:  J F de Leijer; M J H Metman; A van der Hoorn; A H Brouwers; S Kruijff; B M van Hemel; T P Links; H E Westerlaan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

Review 6.  Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy.

Authors:  Frederico F R Maia; Denise Engelbrecht Zantut-Wittmann
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

7.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

8.  Can Ultrasound Predict Malignancy in Patient with Thyroid Cold Nodule?

Authors:  Joko Wiyanto; Achmad Hussein Sundawa Kartamihardja; Trias Nugrahadi
Journal:  World J Nucl Med       Date:  2016-09

9.  Dual time-point 18F-FDG PET/CT imaging with multiple metabolic parameters in the differential diagnosis of malignancy-suspected bone/joint lesions.

Authors:  Chen-Tian Shen; Zhong-Ling Qiu; Zhen-Kui Sun; Wei-Jun Wei; Hong-Jun Song; Xin-Yun Zhang; Quan-Yong Luo
Journal:  Oncotarget       Date:  2017-04-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.